fda warning letters compounded semaglutide tirzepatide 2025 Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling March 31, 2025: Senator asks

4 Effects of residue mutation in the ECD-ECL1 interface on cAMP accumulation

Diarrhea or Constipation: Changes in the speed of your digestive tract can affect how your body processes waste

Keep your eyes peeled for: Proposed rule changes: There was a proposal to reinterpret the Medicare exclusion for anti-obesity drugs so that obesity itself (not just when comorbid with another condition) might be considered a medically accepted indication. But that change was not finalized in April 2025

Q: Is there a risk of seizure

Discussion Integration with Comprehensive Care The evidence suggests that GLP-1 RAs should not be viewed as standalone treatments but rather as components of comprehensive obesity management programs